Literature DB >> 9685642

Activation of procarcinogens by human cytochrome P450 enzymes.

F P Guengerich1, T Shimada.   

Abstract

Enzymatic transformation of most chemical carcinogens is requisite to the formation of electrophiles that cause genotoxicity, and the cytochrome P450 (P450) enzymes are the most prominent enzymes involved in such activation reactions. During the past 15 years the human P450 enzymes have been extensively characterized. Considerable evidence exists that the variation in activity of these enzymes can have important consequences in the actions of drugs. Other studies have been concerned with the activation of procarcinogens by human P450s. Assignments of roles of particular P450s in the metabolism of chemical carcinogens are discussed, along with the current state of evidence for relationships of particular P450s with human cancer. Copyright 1998 Elsevier Science B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9685642     DOI: 10.1016/s0027-5107(98)00037-2

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  48 in total

Review 1.  Contributions of human enzymes in carcinogen metabolism.

Authors:  Slobodan Rendic; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2012-05-10       Impact factor: 3.739

Review 2.  CYP1A1 MspI polymorphism and susceptibility to lung cancer in the Chinese population: an updated meta-analysis and review.

Authors:  Xin Wang; Kai Yue; Li-Ran Hao
Journal:  Int J Clin Exp Med       Date:  2015-08-15

Review 3.  Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2021-01-18       Impact factor: 5.153

Review 4.  Cytochrome P450 humanised mice.

Authors:  Frank J Gonzalez
Journal:  Hum Genomics       Date:  2004-05       Impact factor: 4.639

5.  Binding of diverse environmental chemicals with human cytochromes P450 2A13, 2A6, and 1B1 and enzyme inhibition.

Authors:  Tsutomu Shimada; Donghak Kim; Norie Murayama; Katsuhiro Tanaka; Shigeo Takenaka; Leslie D Nagy; Lindsay M Folkman; Maryam K Foroozesh; Masayuki Komori; Hiroshi Yamazaki; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2013-03-13       Impact factor: 3.739

6.  CYP1A1 polymorphism interactions with smoking status in oral cancer risk: evidence from epidemiological studies.

Authors:  Kai-Tao Yu; Cheng Ge; Xiao-Fang Xu; Jing-Cai Zou; Xuan Zou; Shuai Zhen
Journal:  Tumour Biol       Date:  2014-08-09

7.  Modulation of lung molecular biomarkers by beta-carotene in the Physicians' Health Study.

Authors:  Chun Liu; Xiang-Dong Wang; Lorelei Mucci; J Michael Gaziano; Shumin M Zhang
Journal:  Cancer       Date:  2009-03-01       Impact factor: 6.860

8.  Combined effects of CYP1A1 MspI and GSTM1 genetic polymorphisms on risk of lung cancer: an updated meta-analysis.

Authors:  Wen Li; Li-Qiang Song; Jian Tan
Journal:  Tumour Biol       Date:  2014-06-18

9.  Cytochrome P450 1A1 Ile462Val polymorphism and oral carcinoma risk: an updated meta-analysis including 1,515 cases and 2,233 controls.

Authors:  Xianlu Zhuo; Houyu Zhao; Aoshuang Chang; Huiping Ye; Yan Zhou; Yufeng Song; Yinghui Tan
Journal:  Tumour Biol       Date:  2012-07-31

10.  CYP1A1 MspI polymorphism is associated with prostate cancer susceptibility: evidence from a meta-analysis.

Authors:  Gang Ding; Weiguo Xu; Hedai Liu; Ming Zhang; Qian Huang; Zhijun Liao
Journal:  Mol Biol Rep       Date:  2013-03-09       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.